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Abstract: I n t r o d u c t i o n: A high neutrophil-to-lymphocyte ratio (NLR) has been reported to be 
a strong biomarker of infl ammation.
A i m: We sought to evaluate the impact of NLR on long-term all-cause and cardio-vascular (CV) 
mortality in hemodialysis (HD) patients.
M a t e r i a l  a n d  M e t h o d s: A total of 84 chronic kidney disease (CKD) stage 5 patients with 54 of 
them on HD, with a median age of 61.5 (51.3–74.8) years were enrolled. Th e association between NLR and 
clinical biomarkers was investigated. Multivariable Cox regression analysis was used to fi nd signifi cant 
predictors of all-cause and CV mortality at follow-up.
R e s u l t s: Th e median NLR (interquartile range) was 3.0 (2.1–4.1). Patients with NLR ≥3.9 (the highest 
tertile) had higher fi ve-year all-cause mortality then remaining patients (53.6% vs. 30.4%; p = 0.039). On the 
contrary, only a trend towards increased CV mortality was observed (25.0% vs. 42.9%; p = 0.10). NLR ≥3.9 
was a signifi cant predictor of all-cause mortality at fi ve years [hazard ratio (95%CI): 2.23 (1.10– 4.50); 
p = 0.025] in Cox regression model adjusted for age, gender, and diabetes status. Similarly, while using 
NLR as continuous variable a signifi cant association between NLR and all-cause mortality was confi rmed 
even aft er adjustment for covariates [hazard ratio per 1 unit increase (95%CI): 1.26 (1.06–1.51); p = 0.009] 
with the area under the receiver operating characteristic (ROC) curve of 0.64. Correlations between NLR 
and WBC, concentration of fi brinogen, albumin were observed.
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C o n c l u s i o n s: Asymptomatic infl ammation measured by NLR showed an association with long-term 
all-cause mortality in stage 5 CKD patients, even while white blood cell count was in the normal range.
Key words: neutrophil-to-lymphocyte ratio, CV mortality, all-cause mortality, CKD stage.
Introduction
A high neutrophil-to-lymphocyte ratio (NLR) has been reported to be a strong 
biomarker of acute and chronic infl ammation. NLR is obtained from a complete 
blood count by dividing the number of neutrophils by the number of lymphocytes, 
therefore is inexpensive and widely accessible [1]. Not always the amount of leukocyte 
ratio in complete blood count is above the normal range or the modifi cations in 
percentage composition of morphotic components are changed. Th e extent of minimal 
infl ammation taking part in main vessels and leading to cardiovascular disease (CVD) 
can be predicted by measuring NLR [2]. Interestingly, activated neutrophils are the 
source of neutrophil extracellular traps (NETs). Th e nuclear material (including DNA, 
citrullinated histones, and enzymes of neutrophil granule) released into extracellular 
space, plays a role in the nonspecific immune response and might promote 
infl ammatory reactions and cause tissue damages [3, 4]. NLR has been studied as 
the independent predictor of mortality in heart failure, CVDs [5, 6], cardiothoracic 
surgery, neurological diseases, oncology [7–9], multimorbid medical inpatients [10] 
and also as the predictor of severity and mortality of patients with infectious diseases 
in general population [11, 12].
The prevalence of coronary artery disease (CAD) in patients with  reduced 
kidney two times higher twice than in the general population. Also, an increased 
cardiovascular (CV) mortality is observed in patients with chronic kidney disease 
(CKD), especially those on renal replacement therapy [13, 14]. Yet, traditional risk 
factors for atherosclerosis such as÷ arterial hypertension, diabetes mellitus (DM), 
dyslipidemia, obesity, older age, and male sex are not explaining this dependence. 
Hence, microinflammation, especially asymptomatic, plays an important role in 
the development and progression of endothelial dysfunction and atherogenesis in 
hemodialysis (HD) patients through leukocyte adhesion and infi ltration of the vascular 
endothelium [2, 15, 16]. Multifactorial causes of infl ammation comprise of dialysis-
related and unrelated components. Th e pathogenesis of MIA syndrome (malnutrition, 
infl ammation, atherogenesis) may cause progressive atherosclerotic CVD. Oxidative 
stress leading to endothelial dysfunction and elevated plasma lipoprotein and 
proinfl ammatory cytokines (TNF-α, IL-1, and IL-6) develops chronic infl ammation. 
Also, protein-energy wasting increases susceptibility to infection [17– 24]. According 
to available data, the main mediators of MIA syndrome: low levels of albumin and 
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high levels of CRP and fi brinogen correlates with the high NLR [25, 26]. Th is requires 
further investigations. Th us, we sought to evaluate the impact of NLR on long-term 
all-cause and CV mortality in HD patients.
Materials and Methods
Patients
Th e study population included 84 patients (34 women and 50 men), including 
54  patients on chronic HD. Th e median age was 61.5 (51.3–74.8) years and the 
patients were treated by HD for a median period of 11 years (range, 3.0–38.0 years). 
DM was diagnosed in 25 patients and arterial hypertension in 71 patients. Obesity 
defi ned as body mass index (BMI) ≥25 kg/m2 aff ected 44 patients. Th irty-eight 
patients suff ered from CAD and 18 had previous myocardial infarction. A total of 
45 patients had hyperlipidemia. Patients were followed-up for fi ve years and were 
stratifi ed into tertiles according to NLR at baseline (Table 1).
Table 1. Demographic and biochemical features of the studied population. Results are presented as 
numbers (percentages) or median (interquartile range).
Items/Variables Total (n = 84) NLR <3.9 (n = 56) NLR ≥3.9 (n = 28) P Value
HD 54 (64.3) 38 (67.9) 16 (57.1) 0.33
HD time (HD 
patients only) 11.0 (3.0–38.0) 20.0 (4.0–38.0) 4.0 (1.0–12.0) 0.04
Gender (female) 34 (40.5) 23 (41.1) 11 (39.3) 0.88
Age 61.5 (51.3–74.8) 62.0 (50.0–74.5) 60.0 (53.0–74.5) 0.99
Age >61 years 42 (50.0) 29 (51.8) 13 (46.4) 0.64
BMI 25.1 (22.0–28.5) 24.9 (22.0–28.2) 25.3 (21.6–29.2) 0.87
Overweight 44 (52.4) 28 (50.) 16 (57.1) 0.54
DM 25 (29.8) 15 (26.8) 10 (35.7) 0.40
CAD 38 (45.2) 27 (48.2) 11 (39.3) 0.44
MI 18 (21.4) 14 (25.0) 4 (14.3) 0.26
DVT 21 (25.0) 13 (23.2) 8 (28.6) 0.59
Prior stroke 3 (3.6) 3 (5.4) 0 (0.0) 0.55
HA 71 (84.5) 46 (82.1) 25 (89.3) 0.53
Hyperlipidemia 45 (53.6) 31 (55.4) 14 (50.0) 0.64
Smokers 20 (23.8) 13 (23.2) 7 (25.0) 0.86
WBC 6.9 (5.5–8.1) 6.2 (5.4–7.5) 7.7 (6.3–9.5) 0.002
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Items/Variables Total (n = 84) NLR <3.9 (n = 56) NLR ≥3.9 (n = 28) P Value
NLR 3.0 (2.1–4.1) 2.5 (1.8–3.0) 4.4 (4.1–5.3) <0.001
Fibrinogen 5.2 (4.3–5.9) 5.2 (4.3–5.5) 5.9 (5.0–6.5) 0.020
Creatinine 445.9 (336.9–543.3) 466.4 (355.7–744.1) 410.6 (380.0–522.3) 0.79
eGFR MDRD 10.5 (8.0–14.0) 10.5 (6.0–14.0) 13.0 (10.0–15.0) 0.86
Albumin 42.0 (38.0–44.0) 41.5 (39.0–47.0) 39.0 (37.0–42.0) 0.003
CaxP 3.4 (2.9–4.1) 3.7 (2.8–4.8) 3.0 (2.8–3.7) 0.40
TGF-β1 5638.0 (4013.8–7578.3) 6090.0 (4130.5–6849.5) 5013.0 (3780.0–7702.5) 0.37
Pentraxin 1.4 (0.7–2.2) 1.2 (0.7–2.1) 1.4 (0.7–2.5) 0.82
IL-6 4.0 (2.1–7.5) 3.9 (2.1–6.9) 4.0 (2.4–7.5) 0.85
IL-18 616.0 (496.2–805.4) 609.4 (499.5–775.0) 642.0 (498.4–810.2) 0.70
hsCRP 7.4 (2.1–19.6) 5.9 (2.1–10.3) 16.2 (2.5–24.8) 0.17
MAP 103.3 (96.7–113.3) 103.3 (96.7–113.3) 105.0 (98.4–113.3) 0.16
Fe 10.9 (7.8–13.0) 11.2 (8.6–11.6) 7.9 (6.7–10.4) 0.02
HD — hemodialysis, BMI — body mass index, DM — diabetes mellitus, CAD — coronary artery disease, 
MI  —  myocardial infarction, DVT — deep vein thrombosis, HA — hypertension, WBC — white blood count, 
NLR — neutrophil-to-lymphocyte ratio, eGFR MDRD estimated glomerular fi ltration rate Modifi cation of Diet in 
Renal Disease, CaxP — calcium-phosphorus products, TGFβ1 — transforming growth factor β1, IL — interleukin, 
hsCRP — high-sensitivity C-reactive protein, MAP — mean arterial pressure, Fe — iron.
Ethics statement
Th e study was conducted according to the principles of the Declaration of Helsinki 
and in compliance with the International Conference on Harmonization/Good 
Clinical Practice regulations. Th e study was approved by the Bioethics Committee 
of the Jagiellonian University (KBET/94/B/2011) and all patients signed an informed 
consent for their participation. All the patients were treated at the Department of 
Nephrology, University Hospital in Krakow.
Laboratory tests
Complete blood cell count and serum concentrations of lipids: total cholesterol, HDL-
cholesterol, LDL-cholesterol, triglycerides (TG), serum concentrations of albumin, 
high-sensitivity C-reactive protein (hsCRP), interleukins: IL-6 and IL-18, transforming 
growth factor-β1 (TGFβ1), Pentraxin were assessed in all patients.
Table 1. Cont.
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On the day of blood collection, routine laboratory tests were performed using 
automatic biochemical analysers: Hitachi 917 (Hitachi, Japan) and Modular P (Roche 
Diagnostics, Mannheim, Germany). Serum hs-CRP concentration was determined 
by an immunonephelometric assay using Nephelometer BNII (Siemens, Healthcare 
Diagnostics, Germany). Serum samples for other laboratory tests were aliquoted 
and stored at a temperature below –70°C. Th e measurements of IL-6, TGF-β1 and 
Pentraxin were performed using enzyme-linked immunosorbent assay (ELISA) kits 
(R&D Systems ELISA kits, Minneapolis, United States), while IL-18 with the MBL 
ELISA kit (Nagoya, Japan). Hematological parameters were measured using Sysmex 
XE 2100 Hematological Analyzer (Sysmex Corp., Japan).
Th e NLR was calculated for each patient using absolute neutrophils count (×109/l) 
divided by absolute lymphocytes count (×109/l) from the complete blood count.
Statistical methods
Th e population of patients was stratifi ed into tertiles according to NLR at baseline. 
Categorical variables were expressed as numbers of patients (percentages). Continuous 
variables were expressed as median (interquartile range). Th e association between 
NLR and other biomarkers was assessed using the Pearson’s correlation coeffi  cient (r). 
Survival was estimated using Kaplan–Meier method according to NLR categories. In 
addition, a multivariable Cox proportional hazards model was constructed to identify 
independent predictors of all-cause and CV mortality at follow-up. Variables entered 
in multivariate analysis were age, gender, DM, and hemodialysis status. Results are 
presented as hazard ratios with associated 95% confi dence interval (CI). Receiver 
operating characteristic (ROC) curves analysis was used to assess the predictive ability 
of NLR and other biomarkers. STATISTICA version 13.3 (Tibco Soft ware Inc., Palo 
Alto, CA) was used for analysis and signifi cance was determined at P value of <0.05.
Results
Th e median NLR (interquartile range) was 3.0 (2.1–4.1). Patients with NLR ≥3.9 (the 
highest tertile) had higher fi ve-year all-cause mortality then remaining patients: 53.6% 
vs. 30.4%; p = 0.039 (Fig. 1A). On the contrary, only a trend towards an increased CV 
mortality was observed: 25.0% vs. 42.9%; p = 0.10 (Fig. 1B).
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Fig. 1A. Kaplan–Meier estimates of all-cause mortality.
Fig. 1B. Kaplan–Meier estimates of CV mortality. Patients divided into two groups based on the 
neutrophil-to-lymphocyte ratio (NLR) above and below 3.9.
Aft er adjustment for age, gender, DM, and hemodialysis status in Cox regression 
model, NLR ≥3.9 was a signifi cant predictor of all-cause mortality at 5 years (hazard 
ratio [HR] (95%CI) 2.40 (1.17–4.92); p = 0.017). Similarly, while using NLR as 
continuous variable a signifi cant association between NLR and all-cause mortality 
 Neutrophil-to-lymphocyte ratio predicts long-term all-cause mortality… 61
was confi rmed even aft er adjustment for covariates (HR per 1 unit increase (95%CI) 
1.26 (1.06–1.51); p = 0.010) with an area under the ROC curve of 0.64 (Fig. 2). 
Th e optimal cut off  value of NLR for prediction of all-cause death was ≥4.16 with 
sensitivity and specifi city of 40.6% and 86.5%, respectively. For the used cut off  value 
of ≥3.90, sensitivity and specifi city was 43.8% and 80.8%, respectively.
However, there was no association between NLR and mortality due to heart 
failure, myocardial infarction, infections, neoplasms or stroke (Table 2). Interestingly, 
there were no signifi cant correlations between serum concentration of hs-CRP, IL-6, 
IL-18, TGF β1 and NLR in the studied patients with CKD stage 5. Nonetheless, 
signifi cant correlations were observed between NLR and WBC, as well as, serum 
concentration of fi brinogen and albumin (Table 3).
Fig. 2. Receiver operating curves for NLR, PTX, hsCRP and all-cause death.
Table 2. Five-year mortality stratifi ed by NLR and cause of death. Results are presented as numbers 
(percentages).
Five-year mortality Total (n = 84) NLR <3.9 (n = 56) NLR ≥3.9 (n = 28) P Value
All 32 (38.1) 17 (30.4) 15 (53.6) 0.039
CV-related 26 (31.0) 14 (25.0) 12 (42.9) 0.10
HF-related 18 (21.4) 10 (17.9) 8 (28.6) 0.26
Infection-related 3 (3.6) 2 (3.6) 1 (3.6) 1.00
Neoplasm-related 2 (2.4) 1 (1.8) 1 (3.6) 0.99
MI-related 18 (21.4) 10 (17.9) 8 (28.6) 0.26
Stroke-related 8 (9.5) 4 (7.1) 4 (14.3) 0.43
CV — cardiovascular, HF — heart failure, MI — myocardial infarction
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Table 3. Correlation between NLR and other infl ammatory markers.
NLR IL-18 IL-6 sTNF R II Pentraxin hsCRP
NLR P value
1 0.073 0.031 0.090 0.012 0.030
0.547 0.801 0.457 0.919 0.794
IL-18 P value
0.073 1 0.203 0.425** 0.258* 0.206
0.547 0.071 0.000 0.022 0.078
IL-6 P value
0.031 0.203 1 0.193 0.313** 0.333**
0.801 0.071 0.087 0.005 0.004
sTNF R II P value
0.090 0.425** 0.193 1 0.340** 0.320**
0.457 0.000 0.087 0.002 0.005
Pentraxin P value
0.012 0.258* 0.313** 0.340** 1 0.269*
0.919 0.022 0.005 0.002 0.022
hsCRP P value
0.030 0.206 0.333** 0.320** 0.269* 1
0.794 0.078 0.004 0.005 0.022
* Correlation is signifi cant at the 0.05 level (2-tailed).
** Correlation is signifi cant at the 0.01 level (2-tailed).
NLR — neutrophil-to-lymphocyte ratio, IL — interleukin, sTNFR II — soluble tumor necrosis factor receptor 2, 
hsCRP — high-sensitivity C-reactive protein
Discussion
Our study has confi rmed the usefulness of NLR as a predictor of all-cause mortality 
in patients with CKD stage 5. NLR ≥3.9 was associated with increased long-term 
all-cause mortality, whereas only a trend towards an increased CV mortality was 
observed.
Azab et al. [27] conducted the study to explore the normal range of NLR 
and its relationship with demographics, risk factors and comorbidities in 
a non-institutionalised population of adults in the US. Interestingly, they found that 
such normal value signifi cantly varies with race and they emphasise the necessity to 
adjust NLR cut-off  points to racial diff erences. Authors suggest racial distinctions 
in the infl ammatory response. Additionally, elevated NLR was associated with self-
reported chronic conditions such as DM, CV diseases, smoking or obesity [27].
Previous studies have demonstrated the predictive value of NLR as an infl ammatory 
marker in a variety of diseases but especially were focused on CV diseases in the 
general population. Among others, in few studies, correlations between NLR and 
short- and long-term mortality in patients with myocardial infarction and patients 
undergoing percutaneous coronary interventions were shown [28–31]. Moreover, in 
assays relating to chronic heart failure, it has been presented that NLR is a better 
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predictor of mortality than absolute counts of neutrophils and lymphocytes. On the 
contrary, we confi rmed no correlation between NLR and both chronic heart failure-
related mortality and myocardial infarction-related mortality [32]. Interestingly, 
Dong et al. [33] has shown not only positive association of NLR and GRACE score 
but also that NLR combined with GRACE score gives better predictive value than 
GRACE score alone in predicting CV events in Chinese patients with acute coronary 
syndrome.
Regardless of those studies, only a few concerned patients with CKD or on 
renal replacement therapy. According to Kocyigit et al. [34] worse prognosis and 
faster progression aff ected the ones with a high NLR in patients with stage 4 CKD. 
Likewise, Tatar et al. [35] divided geriatric patients with stage 3–5 CKD into two 
groups: with increased and decreased or stable delta NLR and found the basal 
NLR as the independent predictor of death. Moreover, NLR >3.76 and 3.72 was 
investigated to be a signifi cant and independent predictor of CV events in pre-dialysis 
and dialysis-dependent patients, respectively [36, 37]. Th ough, Altunoren et al. [38] 
found in Cox-regression analysis that NLR is not an independent predictor of CKD 
progression except for advanced CKD stages. Interestingly, some studies showed NLR 
as a simple indicator of contrast induced nephropathy in patients with ST-segment 
elevation myocardial infarction who underwent primary percutaneous coronary 
intervention [39]. According to Bal et al. [40] study, NLR is an independent predictor 
of the extent of coronary artery disease (CAD) in patients with end stage renal disease 
(ESRD). In our research no NLR correlation with myocardial infarction-related death 
was found.
Compellingly, Neuen et al. [41] in multivariate Cox regression showed NLR ≥3.3 
as independently associated with all-cause mortality, as well as, with CV death marker 
in HD patients. Similarly to Han Li et al. study [42] where NLR ≥3.5 was a predictor 
of both all-cause and CV mortality. Correspondingly, An et al. [43] proved that 
peritoneal dialysis patients with NLR >3.5 had an increased risk of overall and CV 
mortality. In Chen et al. [44] study NLR was able to predict clinical outcomes in 
patients with advanced CKD and peripheral artery disease undergoing percutaneous 
transluminal angioplasty.
According to Afari et al. [24] NLR as a marker of CV diseases has a greater 
predictability than total white blood cell (WBC) count or neutrophil count. Some 
studies have demonstrated the association between NLR and infl ammatory markers 
such as TNF-α, CRP, albumin, hemoglobin or total cholesterol [45–47], though in 
our study, apart from serum albumin level, such correlation has not been shown. 
Furthermore, Ahbap et al. [26] demonstrated in ESRD population on HD a signifi cant 
positive correlation between NLR and hsCRP. Similar NLR and CRP positive 
association was found in Pineault et al. study [25]. However, this study showed 
inverse correlation with albumin in patients receiving chronic dialysis. In the cross-
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sectional study of Th ijssen [48], parameters such as age, access type, and variables 
of 3 domains: nutrition, dialysis parameters and infl ammation measured by WBC, 
NLR, and hemoglobin, were related to serum albumin. Ozcicek et al. [49] found NLR 
as a predictor of epicardial adipose tissue in HD patients. In geriatric population 
elevated NLR was an independent factor to predict the malnutrition or the risk of 
malnutrition [50] as well as an indicator of fracture presence, risk factor and moderate 
predictor of postoperative myocardial injury, high infl ammatory response/infection 
and in-hospital death [51]. In HD patients study NLR better predicted mortality in 
addition to demographics, comorbidities, and serum albumin [52]. In results from 
2 international cohort studies increased CRP levels >10.0 mg/l was observed with 
the combination of high NLR and low albumin levels [53]. According to Chittawar 
et al. [54] analysis of Indian population revealed a signifi cantly higher occurrence of 
diabetic nephropathy, albuminuria, retinopathy and coronary artery disease (CAD) 
among patients in higher quartiles of NLR. Th ey have long standing DM and lower 
GFR. NLR was the best independent predictor of the occurrence of microvascular 
complications in patients with DM type 2. Another study showed a significant 
corelation between NLR and diabetic nephropathy, especially in early stages [55].
Th ere are many studies based on cancer patients groups showing NLR/albumin 
ratio as an independent prognostic factor of overall survival [56–58].
Interestingly, also lymphopenia can be associated with progression of athero-
sclerosis  [59]. Moreover, De Jager et al. [60] found that NLR and lymphocytope-
nia are better predictors of bacteriemia in adult patients admitted to Emergency 
Department than routine parameters like CRP level, WBC count and neutrophil 
count. However, in our study among HD patients, no association with infectious 
mortality was found.
Some studies on patients with different kinds of neoplasms have shown the 
composition of preoperative or pretreatment plasma fi brinogen level and NLR as 
a combined score called F-NLR. Marchetti et al. [61] divided F-NLR into 3 groups 
(group 0 for both low markers, group 1 for low NLR and high fi brinogen and group 2 
for both high markers) and identifi ed their prediction of prognosis and response to 
treatment in patients with ovarian cancer. F-NLR was investigated as the independent 
prognostic factor for the disease-free survival and overall survival (for patients with 
small cell lung cancer and hypopharyngeal squamous cell cancer [62] or advanced 
epithelial tumor cancer [63, 64]). Fu et al. [65] showed that F-NLR enhances 
prognostic value for hepatocellular carcinoma patients and their poor outcomes. 
According to Arigami et al. [66] study, F-NLR can be a clinical predictor of response 
to treatment (chemotherapy and chemoradiotherapy) in patients with gastric cancer. 
Moreover, in Liu et al. [67] study postoperative F-NLR score for outcomes in gastric 
cancer independently predicted overall survival, However, in similar study of lung 
adenosquamous cancer the combination of postoperative NLR, PLT, PLR (platelet-
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to-lymphocyte ratio) and fibrinogen called CO-NPF had grater prognostic value 
than NLR, fibrinogen, PLT or PLR separately [68]. Interestingly, F-NLR may be 
used as a way to distinguish between the non muscle-invasive and muscle-invasive 
bladder cancer [69]. To our best knowledge, there are no investigations showing the 
association between NLR and fi brinogen in patients on HD. In our study we found 
a correlation between NLR and fi brinogen.
The relationship between NLR and atherosclerosis has several theories and 
explanations such us a direct role of neutrophils in early endothelial dysfunction, 
atherogenesis and plaque destabilization [2, 15, 16]. Recently, the NETs and its marker 
of formation — circulating cell-free DNA are demonstrated to promote infl ammation 
and to predict mortality in HD patients [70, 71]. According to Jwa-Kyunget et al. 
study, blood urea nitrogen and creatinine levels were not associated with NET levels, 
but interestingly, whole blood WBC and neutrophil counts were signifi cantly elevated 
in patients with an increased NET formation, as were NLR and hs-CRP levels. 
Furthermore, baseline NET formation correlated positively with CAD, peripheral 
neutrophil count and infl ammatory markers such as NLR and hs-CRP. Moreover, 
multivariate analyses identifi ed the prevalence of CAD and neutrophil counts as 
independent predictors of baseline NET formation [72]. Still, many facts concerned 
with chronic, low-grade infl ammation and atherosclerosis, especially among patients 
with CKD treated by HD need more and deep investigations. Consequently, little 
is known about the interpretation of the fi ndings of infl ammatory markers in the 
clinical setting. Nevertheless, in practical fi ndings, NLR above a certain value might 
induce changing or initiating treatment as in the cease of CRP use. Th us, low-cost and 
easily available measurement are the strong advantages to prompt to consider NLR 
as a  predictor of all-cause mortality. Yet, large studies should be undertaken before 
a wide clinical practice acquaintance.
Study limitations
Th e main study limitation was the single measurement of complete blood count on 
admission. Th erefore, the changes in NLR were not evaluated. Moreover, patients 
with DM should be excluded. NLR may be superior for identifying subclinical 
infl ammation but further studies are needed to clarify its indications and limitations.
Conclusions
Asymptomatic infl ammation measured by NLR showed an association with long-term 
all-cause mortality in CKD stage 5 patients, even while white blood cell count was in 
the normal range. As a cheap and convenient marker NRL can be useful in identifying 
CKD stage 5 patients at a high-risk of mortality at long-term follow-up.
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